Vapotherm Inc.

75 articles with Vapotherm Inc.

• Vapotherm Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results

  1/13/2021

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced certain preliminary unaudited fourth quarter and full year 2020 revenue results.

• Vapotherm to Present at the 23rd Annual ICR/Westwicke Conference

  1/7/2021

  Vapotherm to Present at the 23 rd Annual ICR/Westwicke Conference

• Vapotherm Wins Prestigious Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists

  12/4/2020

  Vapotherm, Inc. (NYSE:VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® systems, has been awarded the prestigious American Association for Respiratory Care Zenith Award.

• Vapotherm Updates Its Fourth Quarter and Fiscal Year 2020 Outlook

  12/1/2020

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced an update to its fourth quarter and fiscal year 2020 revenue guidance given on November 4, 2020.

• Vapotherm Reports Third Quarter 2020 Financial Results

  11/4/2020

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced third quarter 2020 financial results.

• Vapotherm Announces Appointment of Donald Spence to Board of Directors and the Resignations of Craig Reynolds and Geoff Pardo

  10/23/2020

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced the appointment of Donald Spence to the Company’s Board of Directors. Mr. Spence will serve as a member and chair of the Compensation Committ

• Vapotherm Announces Closing of Debt Refinancing

  10/22/2020

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced that it has entered into a loan and security agreement with CIBC Innovation Banking that provides the Company with up to $52 million in debt financing through a combination of a term loan facility and a revolving credit facility

• Vapotherm to Report Third Quarter 2020 Financial Results

  10/21/2020

  Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today announced that it will release financial results for the third quarter of 2020 after the close of trading on Wednesday, November 4, 2020

• New ‘Negative Pressure Scavenger Kit’ Helps Hospitals Manage Infectious Particles When Treating Patients with COVID-19, Supports Non-Profits Supporting COVID-19 Front-Line Clinicians

  8/12/2020

  Vapotherm, Inc. announced the release of a low-cost, easy to use kit to help clinicians create a zone of relative negative pressure at the patient's face which may mitigate the risk of transmission of potentially infectious particles while treating COVID-19 patients.

• Vapotherm to Present at the Canaccord Genuity 40th Annual Growth Conference

  8/6/2020

  Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 via webcast.

• Vapotherm Reports Second Quarter 2020 Financial Results

  8/4/2020

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced second quarter 2020 financial results.

• Vapotherm to Report Second Quarter 2020 Financial Results

  7/21/2020

  Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of Vapotherm’s proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2020 after the close of trading on Tuesday, August 4, 2020.

• Vapotherm to Expand Production Capacity in Advance of Potential Increase in Demand for High-Flow Nasal Cannula Systems for Treating COVID-19 Respiratory Distress

  6/4/2020

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients suffering from respiratory distress, announced a major expansion in its capital equipment manufacturing capabilities.

• Vapotherm to Present at the William Blair 40th Annual Growth Stock Conference

  6/3/2020

  Vapotherm, Inc. announced that its management team will be presenting at the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020 via webcast.

• Vapotherm to Present at the Bank of America Securities Virtual Health Care Conference 2020

  5/11/2020

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be presenting at the Bank of America Securities Health Care Conference 2020 on Thursday, May 14, 2020 via webcast.

• Vapotherm Announces Pricing of Public Offering of Common Stock - May 07, 2020

  5/7/2020

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced the pricing of an underwritten public offering of 3,350,000 shares of its common stock at a price to the public of $26.00 per share.

• Vapotherm Announces Proposed Public Offering of Common Stock - May 06, 2020

  5/6/2020

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced the commencement of a proposed public offering of $75 million of its shares of common stock.

• Vapotherm Reports First Quarter 2020 Financial Results

  5/5/2020

  Vapotherm, Inc.,, a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced first quarter 2020 financial results.

• Vapotherm to Report First Quarter 2020 Financial Results

  4/21/2020

  Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2020 after the close of trading on Tuesday, May 5, 2020.

• Vapotherm Reports Preliminary First Quarter 2020 Financial Results

  4/13/2020

  April 13, 2020 11:00 UTC Preliminary first quarter revenue of approximately $18.9 million represents 54% increase as compared to the first quarter of 2019